Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Fenofibrate119 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00348 | 35126113 | Front Pharmacol | Fenofibrate Improves Insulin Resistance and Hepatic Steatosis and Regulates the Let-7/SERCA2b Axis in High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease Mice. | 2022 | Details |
| A00595 | 35035496 | Evid Based Complement Alternat Med | Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway. | 2022 | Details |
| A00725 | 34988225 | Biomed Res Int | Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis. | 2021 | Details |
| A00796 | 34964438 | Elife | Hepatic MIR20B promotes nonalcoholic fatty liver disease by suppressing PPARA. | 2021 | Details |
| A01785 | 34618982 | FASEB J | Omega-3 carboxylic acids and fenofibrate differentially alter plasma lipid mediators in patients with non-alcoholic fatty liver disease. | 2021 | Details |
| A01843 | 34593018 | BMC Pharmacol Toxicol | Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis. | 2021 | Details |
| A01877 | 34576091 | Int J Mol Sci | Establishment of an Adult Medaka Fatty Liver Model by Administration of a Gubra-Amylin-Nonalcoholic Steatohepatitis Diet Containing High Levels of Palmitic Acid and Fructose. | 2021 | Details |
| A02352 | 34406209 | Braz J Med Biol Res | α,β-Amyrin prevents steatosis and insulin resistance in a high-fat diet-induced mouse model of NAFLD via the AMPK-mTORC1-SREBP1 signaling mechanism. | 2021 | Details |
| A02426 | 34374658 | J Physiol Pharmacol | Hesperidin, a novel candidate for the successful treatment of high fat diet plus ethanol-induced fatty liver disease in mice. | 2021 | Details |
| A02682 | 34285335 | Exp Mol Med | Loss of Acot12 contributes to NAFLD independent of lipolysis of adipose tissue. | 2021 | Details |
| A03107 | 34128328 | Chem Biodivers | Effect of Compounds from Moringa oleifera Lam. on in Vitro Non-Alcoholic Fatty Liver Disease (NAFLD) Model System. | 2021 | Details |
| A03200 | 34092291 | Chin J Nat Med | Silybin alleviates hepatic lipid accumulation in methionine-choline deficient diet-induced nonalcoholic fatty liver disease in mice via peroxisome proliferator-activated receptor α. | 2021 | Details |
| A03492 | 33984335 | Metabolism | Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy. | 2021 | Details |
| A06708 | 32774420 | Evid Based Complement Alternat Med | Anti-inflammatory Mechanism of Ruzu Bitters on Diet-Induced Nonalcoholic Fatty Liver Disease in Male Wistar Rats. | 2020 | Details |
| A06759 | 32757283 | Fundam Clin Pharmacol | Protective effect of fenofibrate against high-fat-high-fructose diet induced non-obese NAFLD in rats. | 2020 | Details |
| A07125 | 32613381 | Cell Biol Toxicol | Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists. | 2020 | Details |
| A07769 | 32360434 | J Hepatol | Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆. | 2020 | Details |
| A07793 | 32353385 | Toxicol Appl Pharmacol | Metabolomic-based assessment reveals dysregulation of lipid profiles in human liver cells exposed to environmental obesogens. | 2020 | Details |
| A07807 | 32350271 | Nat Commun | Partial impairment of insulin receptor expression mimics fasting to prevent diet-induced fatty liver disease. | 2020 | Details |
| A08125 | 32239031 | Chem Commun (Camb) | Simultaneous co-assembly of fenofibrate and ketoprofen peptide for the dual-targeted treatment of nonalcoholic fatty liver disease (NAFLD). | 2020 | Details |
| A09256 | 31816064 | Hum Mol Genet | Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia. | 2020 | Details |
| A09854 | 31591263 | Mol Cell Proteomics | Absolute Quantification of Apolipoproteins Following Treatment with Omega-3 Carboxylic Acids and Fenofibrate Using a High Precision Stable Isotope-labeled Recombinant Protein Fragments Based SRM Assay. | 2019 | Details |
| A09918 | 31560861 | Can J Physiol Pharmacol | β-Sitosterol mitigates the development of high-fructose diet-induced nonalcoholic fatty liver disease in growing male Sprague-Dawley rats. | 2019 | Details |
| A10243 | 31414497 | J Sci Food Agric | Quercetin administration post-weaning attenuates high-fructose, high-cholesterol diet-induced hepatic steatosis in growing, female, Sprague Dawley rat pups. | 2019 | Details |
| A12328 | 30514673 | Nan Fang Yi Ke Da Xue Xue Bao | [Effects of sera of rats fed with Huganqingzhi tablets on endoplasmic reticulum stress in a HepG2 cell model of nonalcoholic fatty liver disease]. | 2018 | Details |
| A12365 | 30483596 | JGH Open | Kombiglyze (metformin and saxagliptin)-induced hepatotoxicity in a patient with non-alcoholic fatty liver disease. | 2018 | Details |
| A12983 | 30197273 | J Clin Lipidol | Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study. | 2018 | Details |
| A12998 | 30188729 | Mol Pharm | Polyurethane Nanoparticle-Loaded Fenofibrate Exerts Inhibitory Effects on Nonalcoholic Fatty Liver Disease in Mice. | 2018 | Details |
| A13065 | 30154499 | Sci Rep | The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity. | 2018 | Details |
| A13145 | 30116360 | Exp Ther Med | 2,3,5,4'-tetrahydroxy-stilbene-2-O-β-D-glucoside attenuates methionine and choline-deficient diet-induced non-alcoholic fatty liver disease. | 2018 | Details |
| A13174 | 30100243 | Mol Metab | Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context. | 2018 | Details |
| A13453 | 29964161 | Pharmacol Res | Human-based systems: Mechanistic NASH modelling just around the corner? | 2018 | Details |
| A13533 | 29927747 | J Complement Integr Med | Terminalia Sericea aqueous leaf extract protects growing wistar rats against fructose-induced fatty liver disease. | 2018 | Details |
| A13724 | 29790582 | Hepatology | Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents. | 2018 | Details |
| A14846 | 29207101 | Int J Mol Med | Diosgenin prevents high-fat diet-induced rat non-alcoholic fatty liver disease through the AMPK and LXR signaling pathways. | 2017 | Details |
| A14940 | 29164820 | Liver Int | Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. | 2017 | Details |
| A14995 | 29132235 | SLAS Discov | A Cell-Based Assay to Investigate Hypolipidemic Effects of Nonalcoholic Fatty Liver Disease Therapeutics. | 2017 | Details |
| A15254 | 29023319 | Eur J Gastroenterol Hepatol | Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease. | 2017 | Details |
| A15500 | 28874443 | J Lipid Res | Amelioration of diet-induced steatohepatitis in mice following combined therapy with ASO-Fsp27 and fenofibrate. | 2017 | Details |
| A16146 | 28539716 | Pharmacogn Mag | Prevention Mechanism of 2,3,5,4'-Tetrahydroxy-stilbene-2-O-β-D-glucoside on Lipid Accumulation in Steatosis Hepatic L-02 Cell. | 2017 | Details |
| A16762 | 28195199 | Sci Rep | Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. | 2017 | Details |
| A16782 | 28179883 | Front Pharmacol | New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease. | 2017 | Details |
| A16804 | 28163820 | Oxid Med Cell Longev | Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death. | 2017 | Details |
| A16811 | 28159867 | J Lipid Res | Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase. | 2017 | Details |
| A16890 | 28109099 | Nan Fang Yi Ke Da Xue Xue Bao | [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease]. | 2017 | Details |
| A16936 | 28084058 | J Diabetes Investig | Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice. | 2017 | Details |
| A17125 | 27979751 | J Hepatol | PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease. | 2016 | Details |
| A17175 | 27930988 | Biomed Pharmacother | Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats. | 2016 | Details |
| A17251 | 27889747 | Cell Physiol Biochem | Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells. | 2016 | Details |
| A17324 | 27845265 | J Ethnopharmacol | The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells. | 2016 | Details |
| A17982 | 27438910 | Nanomedicine | Fenofibrate nanoliposome: Preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice. | 2016 | Details |
| A17986 | 27435856 | Mol Cell Biochem | FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. | 2016 | Details |
| A18506 | 27085785 | Metabolism | Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. | 2015 | Details |
| A18717 | 26983476 | Zhonghua Gan Zang Bing Za Zhi | [Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease]. | 2016 | Details |
| A18746 | 26973390 | World J Gastroenterol | Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression. | 2016 | Details |
| A18976 | 26838599 | Gut | Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. | 2016 | Details |
| A19001 | 26825546 | Eur J Pharmacol | Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression. | 2016 | Details |
| A19157 | 26724391 | Eur J Pharmacol | Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model. | 2015 | Details |
| A19491 | 26524364 | Zhonghua Gan Zang Bing Za Zhi | [Effects of fenofibrate on hepatocyte apoptosis in nonalcoholic fatty liver]. | 2015 | Details |
| A19656 | 26433207 | Diabet Med | Low alanine aminotransferase levels and higher number of cardiovascular events in people with Type 2 diabetes: analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. | 2015 | Details |
| A20041 | 26194065 | Cytokine | PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats. | 2015 | Details |
| A20450 | 25956613 | Hepatol Int | Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease. | 2015 | Details |
| A20545 | 25896720 | Pharmacology | Fenofibrate treatment attenuated chronic endoplasmic reticulum stress in the liver of nonalcoholic fatty liver disease mice. | 2015 | Details |
| A20643 | 25837920 | J Pharmacol Sci | Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats. | 2014 | Details |
| A20888 | 25661699 | Int Immunopharmacol | Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats. | 2015 | Details |
| A20981 | 25604802 | Expert Opin Investig Drugs | Early investigational drugs targeting PPAR-α for the treatment of metabolic disease. | 2015 | Details |
| A21968 | 24926685 | PLoS One | Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect. | 2014 | Details |
| A22301 | 24680992 | J Ethnopharmacol | In vitro effects of active components of Polygonum Multiflorum Radix on enzymes involved in the lipid metabolism. | 2014 | Details |
| A22471 | 24534255 | Toxicol Appl Pharmacol | PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. | 2014 | Details |
| A22598 | 24428677 | Expert Opin Pharmacother | New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. | 2014 | Details |
| A22668 | 24374462 | Cochrane Database Syst Rev | Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. | 2013 | Details |
| A22672 | 24373179 | Diabetes Obes Metab | APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome. | 2014 | Details |
| A23059 | 24073298 | World J Hepatol | Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. | 2013 | Details |
| A23150 | 24002947 | Hepatology | Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. | 2014 | Details |
| A24159 | 23169785 | Am J Physiol Endocrinol Metab | Pex11α deficiency impairs peroxisome elongation and division and contributes to nonalcoholic fatty liver in mice. | 2012 | Details |
| A24267 | 23063693 | Biochimie | A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα. | 2012 | Details |
| A24543 | 22770622 | Expert Opin Pharmacother | The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges. | 2012 | Details |
| A25343 | 21946149 | Exp Mol Pathol | Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis. | 2011 | Details |
| A25697 | 21529810 | Atherosclerosis | PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH. | 2011 | Details |
| A25772 | 21475632 | Int J Gen Med | The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage. | 2011 | Details |
| A25774 | 21474829 | Arterioscler Thromb Vasc Biol | Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. | 2011 | Details |
| A26054 | 21160985 | World J Hepatol | Combination drug treatment in patients with non-alcoholic fatty liver disease. | 2010 | Details |
| A26560 | 20204774 | Adv Exp Med Biol | Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. | 2010 | Details |
| A26600 | 20114046 | FEBS Lett | Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. | 2010 | Details |
| A27421 | 18417155 | Life Sci | The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. | 2008 | Details |
| A27500 | 18261709 | Dig Liver Dis | A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. | 2008 | Details |
| A27537 | 18171348 | J Gastroenterol Hepatol | PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes. | 2008 | Details |
| A27577 | 17935056 | Diab Vasc Dis Res | The role of fenofibrate in clinical practice. | 2007 | Details |
| A27870 | 17201732 | Clin Exp Pharmacol Physiol | Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. | 2007 | Details |
| A28006 | 16762007 | Liver Int | Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. | 2006 | Details |
| A28016 | 16709309 | Curr Med Res Opin | Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. | 2006 | Details |
| A28089 | 16466828 | J Hepatol | Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates. | 2005 | Details |
| A28794 | 34999207 | Clin Gastroenterol Hepatol | Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat. | 2022 | Details |
| A30665 | 32025605 | Hepatol Commun | Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice. | 2019 | Details |
| A32608 | 28003852 | Evid Based Complement Alternat Med | Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARα and L-FABP Expressions in High-Fat-Fed Rats. | 2016 | Details |
| A42643 | 33916086 | Int J Mol Sci | Fenofibrate Regulates Visceral Obesity and Nonalcoholic Steatohepatitis in Obese Female Ovariectomized C57BL/6J Mice. | 2021 | Details |
| A45235 | 25565897 | HIV AIDS (Auckl) | Managing dyslipidemia in HIV/AIDS patients: challenges and solutions. | 2014 | Details |
| A45387 | 24875102 | Am J Physiol Gastrointest Liver Physiol | Human FABP1 T94A variant impacts fatty acid metabolism and PPAR-α activation in cultured human female hepatocytes. | 2014 | Details |
| A46209 | 20371660 | J Clin Endocrinol Metab | Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. | 2010 | Details |
| A46321 | 19553925 | Obesity (Silver Spring) | Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. | 2009 | Details |